Sanofi unveils Phase 3 trial results of isatuximab combination therapy
Category: #health  By Mateen Dalal  Date: 2019-06-04
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Sanofi unveils Phase 3 trial results of isatuximab combination therapy

The French multinational pharmaceutical company Sanofi has reportedly announced crucial Phase 3 ICARIA-MM trial results which revealed that isatuximab aided with dexamethasone and pomalidomide (isatuximab combination therapy) has shown statistically substantial improvements compared to pomalidomide and dexamethasone (pom-dex) alone in patients enduring relapsed/refractory multiple myeloma (RRMM). The results were recently presented at annual meeting in Chicago at the 2019 American Society of Clinical Oncology (ASCO).

Paul Richardson, MD, clinical program leader, principal investigator, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, reportedly stated that Isatuximab added to pomalidomide and dexamethasone has resulted in remarkable 40 percent decrease in the risk of progression or demise in comparison with pomalidomide and dexamethasone alone. The result is significant because the study included a particularly relapsed, refractory and difficult-to-treat patient population, which was highly reflecting real-world practice, he further added.

Reportedly, Isatuximab combination therapy has shown a statistically significant improvement in progression free survival, and the median progression free survival was longer in the isatuximab combination therapy arm than pom-dex alone.

Apparently, ICARIA-MM is a crucial Phase 3 open-label, randomized, multi-center study assessing isatuximab combined with pom-dex against pom-dex alone in patients enduring RRMM. Around 307 patients suffering from RRMM have been enrolled in the study at around 96 centers in 24 nations. Overall, patients were given a median of 3 prior lines of anti-myeloma treatments which includes minimum 2 sequential cycles of a proteasome inhibitor and lenalidomide given alone or in combination.

During the study, Isatuximab was dispensed via an intravenous infusion at a dose of 10mg/kg once weekly for 4 weeks and further every other week for 28-day cycles combined with pom-dex standard doses for the period of therapy.

For the record, Isatuximab is an experimental monoclonal antibody which targets a particular epitope on the CD38 receptor of a plasma cell.

 

Source link: http://hugin.info/152918/R/2245494/886977.pdf

https://www.finanznachrichten.de/nachrichten-2019-06/46854851-sanofi-phase-3-trial-of-isatuximab-combination-therapy-showed-40-reduction-in-the-risk-of-disease-progression-or-death-for-patients-with-relapsed-re-399.htm

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...